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Abstract
Introduction: The effects of dopexamine, a b2-agonist, on perioperative and sepsis-related hemodynamic,
microvascular, immune, and organ dysfunction are controversial and poorly understood. We investigated these
effects in a rodent model of laparotomy and endotoxemia.
Methods: In two experiments, 80 male Wistar rats underwent laparotomy. In 64 rats, this was followed by
administration of endotoxin; the remainder (16) underwent sham endotoxemia. Endotoxemic animals received
either dopexamine at 0.5, 1, or 2 μg/kg/min or 0.9% saline vehicle (controls) as resuscitation fluid. The effects of
dopexamine on global hemodynamics, mesenteric regional microvascular flow, renal and hepatic function and
immune activation were evaluated.
Results: Endotoxin administration was associated with a systemic inflammatory response (increased plasma levels
of tumor necrosis factor (TNF)-a, interleukin (IL)-1b, IL-6, and IL-10, as well as cell-adhesion molecules CD11a and
CD11b), and increased pulmonary myeloperoxidase (MPO) activity (indicating pulmonary leukocyte infiltration),
whereas biochemical changes demonstrated lactic acidosis with significant renal and hepatic injury. Dopexamine
administration was associated with less-severe lactic acidosis (pooled dopexamine versus controls, (lactate, 2.2 mM
± 0.2 mM versus 4.0 mM ± 0.5 mM; P < 0.001) and reductions in the systemic inflammatory response (pooled
dopexamine versus control, 4 hour (TNF-a): 324 pg/ml ± 93 pg/ml versus 97 pg/ml ± 14 pg/ml, p < 0.01),
pulmonary myeloperoxidase (MPO) activity, and hepatic and renal injury (pooled dopexamine versus control (ALT):
81 IU/L ± 4 IU/L versus 138 IU/L ± 25 IU/L; P < 0.05; (creatinine): 49.4 μM ± 3.9 μM versus 76.2 μM ± 9.8 μM; P <
0.005). However, in this study, clinically relevant doses of dopexamine were not associated with clinically significant
changes in MAP, CI, or gut regional microvascular flow.
Conclusions: In this model, dopexamine can attenuate the systemic inflammatory response, reduce tissue
leukocyte infiltration, and protect against organ injury at doses that do not alter global hemodynamics or regional
microvascular flow. These findings suggest that immunomodulatory effects of catecholamines may be clinically
significant when used in critically ill surgical patients and are independent of their hemodynamic actions.
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Introduction
A growing body of evidence suggests that the potential
exists to reduce the morbidity and unacceptably high
mortality rates associated with major surgery in high-risk
patients [1]. For many years, inotropic and vasoactive
agents have been widely used to maintain tissue perfu-
sion in critically ill and high-risk surgical patients with
the aim of improving clinical outcomes [2]. Dopexamine
is a dopamine analogue with agonist activity at b2 and
dopaminergic receptors. This spectrum of activity confers
vasodilator actions in addition to chronotropic and mild
inotropic effects. Postoperative complications occur more
frequently in the presence of poor tissue microvascular
flow and oxygenation [3-5], and dopexamine has been
shown to improve these abnormalities [6]. However, the
effect of dopexamine on clinical outcomes is less clear,
and the findings of randomized trials have proved incon-
sistent [6-11]. These conflicting findings might be
explained by dose-related differences in the hemody-
namic and immunologic effects of dopexamine [12].
Increasing recognition is building that adrenergic agents
may have important metabolic and immunologic actions
[13,14], whereas tachycardia and myocardial ischemia may
cause significant harm, especially at higher doses. It has
been suggested that anti-inflammatory actions may be
beneficial [13,15]. Previous work indicated that dopexa-
mine may decrease leukocyte-endothelial adhesion in
mesenteric venules [16,17], a phenomenon dependent on
CD11a and CD11b integrins [18]. Other adrenergic agents
have also been shown to exert antiinflammatory actions
on cytokine responses in immune cells [15,19,20]. It is
possible that the proposed clinical benefits of dopexamine,
particularly at low doses, may relate to actions on inflam-
matory pathways [21]. Our objective was to investigate the
effects of dopexamine on global hemodynamics, regional
microvascular flow, systemic inflammatory response, and
organ injury in a rodent model of laparotomy and
endotoxemia.
Materials and methods
Eighty male Wistar rats (220 to 410 g) received a standard
diet and water ad libitum before experiments (two experi-
ments used 40 rats divided into five groups and shared a
common anesthetic and early surgical procedure, as detailed
later). All procedures were performed with institutional
approval and in accordance with the Home Office Guidance
on the Operation of Animals (Scientific Procedures) Act,
1986. Anaesthesia was induced by intraperitoneal injection
of thiopental (120 mg/kg) and maintained with supplemen-
tary injections administered according to regular testing for
limb withdrawal to a standard stimulus or signs of inade-
quate anaesthesia. Animals were placed on a heated mat
and maintained at 37 ± 0.5°C. A tracheostomy was per-
formed, following which a short section of polyethylene
tubing (internal diameter, 1.67 mm) was inserted to main-
tain airway patency and to facilitate spontaneous respira-
tion. The right carotid artery was cannulated to allow blood
sampling and continuous monitoring of heart rate (HR) and
mean arterial pressure (MAP). The left jugular vein was
cannulated for drug and fluid administration. A 2-cm mid-
line incision was then made through the abdominal wall to
expose the small intestine. This completed the shared early
surgical procedure (further surgery was performed, as speci-
fied in later sections for each of the two experiments). After
the completion of surgery and stabilization in both experi-
ments, this protocol was followed: endotoxemia was
induced in four of five groups by administration of Escheri-
chia coli lipopolysaccharide (LPS) 0111:B4 (6 mg/kg) over a
10-minute period (sham group received 0.9% saline vehicle).
Administration of LPS was followed by 4 hours of fluid
resuscitation with an infusion of intravenous 0.9% saline at
4.3 ml/kg/h. Sham and control animals received only 0.9%
saline infusion. Three different concentrations of dopexa-
mine were added to the remaining three groups’ infusion
fluid, producing dopexamine infusion rates of 0.5, 1, and 2
μg/kg/min for groups D0.5, D1, and D2, respectively. The
experiment ended after 4 hours of resuscitation when the
lungs and heart were harvested en bloc. In experiment 1,
the lungs were flash frozen in liquid nitrogen before being
stored at -80°C for subsequent analysis.
Experiment 1
In the first set of 40 rats, after the early shared surgical
procedure, a loop of intestine adjoining the terminal ileum
was exteriorized and placed in a Saran receiving pouch. A
baseline set of arterial blood samples was then taken, the
volume being replaced with an equal volume of 0.9% sal-
ine. Animals were allowed to stabilize for 15 minutes
before being randomized to one of five groups: sham, con-
trol, D0.5, D1, or D2. Each group contained eight animals,
and all animals underwent surgery and resuscitation. Only
sham animals did not receive LPS, whereas neither sham
nor control animals received dopexamine.
Measurement of plasma lactate, base deficit, and indices of
renal and hepatic injury
A 200-μl blood sample was taken at baseline and at the
end of the experiment for measurement of plasma lac-
tate concentration (Accutrend Lactate; Roche Diagnos-
tics, Basel, Switzerland) and base deficit (Radiometer,
Copenhagen, Denmark). A 1-ml blood sample was also
taken at the end of experiment for the measurements of
urea, creatinine, alanine aminotransferase (ALT), and
aspartate aminotransferase (AST) by a commercial
veterinary laboratory (IDEXX Laboratories Ltd, Sussex,
UK), who were blinded to treatment.
Measurement of plasma cytokine levels
A 200 μl blood sample was taken for measurement of
plasma cytokine levels at baseline, 60 minutes after LPS
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administration, and at the end of the experiment.
Samples were centrifuged immediately at 9,900 g for
3 minutes. A minimum of 50 μl of plasma per sample
was collected and stored at -80°C for subsequent analysis.
Cytokine levels were measured on a Luminex 200 reader
(Luminex Co., Austin, TX, USA) by using the Rat Cyto-
kine 10-Plex kit (Invitrogen Corporation, Camarillo, CA,
USA) and following manufacturer’s instructions. Mea-
surements were expressed as mean fluorescent intensity,
which was converted to pictograms per milliliter by using
a set of nonlinear transforms based on standard curves
created in PrismGraph 4.0 (GraphPad Software Inc., San
Diego, CA, USA).
Measurement of pulmonary myeloperoxidase levels
MPO was measured in samples of pulmonary tissue from
lungs harvested at the end of the experiment. These sam-
ples were stored at -80°C and were analyzed in four ran-
domly selected lung samples per group by colleagues who
were blinded to treatment. Samples of tissue from the
right lung were homogenized in a solution containing
0.5% (wt/vol) hexadecyltrimethyl-ammonium bromide dis-
solved in 10 mM potassium phosphate buffer (pH 7) and
centrifuged for 30 minutes at 20,000 g at 4°C. An aliquot
of the supernatant was then allowed to react with a solu-
tion of 1.6 mM tetramethylbenzidine and 0.1 mM H2O2.
The rate of change in absorbance was measured spectro-
photometrically at 650 nm. MPO activity was defined as
the quantity of enzyme degrading 1 μmol of peroxide per
minute at 37°C and was expressed in microunits per gram
wet tissue.
Measurement of neutrophil cell surface expression
of CD11a and CD11b
Phycoerythrin and fluorescein isothiocyanate-conjugated
mouse monoclonal antibodies (mAbs) against CD11a
(IgG2a) and CD11b (IgA) were used to quantify neutrophil
cell-surface expression of these markers. Isotype-, fluoro-
chrome-, and protein concentration-matched controls
were run in parallel to the mAb (Becton Dickinson,
Oxford, UK). Heparinized blood (600 μl) was collected for
flow-cytometric analysis of leukocyte adhesion molecules,
and 100 μl of whole blood was mixed with mAb against
rat CD11a (5 μl) or CD11b (3 μl) in 4 × 75-mm polystyr-
ene test tubes. Blood with no antibody added served as a
control for autofluorescence. The test tubes were then
incubated on ice for 30 minutes with continuous shaking,
protected from light. Erythrocytes were lysed by addition
of 2 ml FACSTM lysing solution to the test tubes. The
samples were then incubated for a further 10 minutes
on ice in the dark, and then centrifuged at 1,000 g for
3 minutes at 4°C. The supernatant was discarded, and the
leukocyte pellet was resuspended and washed twice in
2 ml ice-cold optimized PBS cell wash. Finally, leukocytes
were fixed in 0.3 ml 1% wt/vol paraformaldehyde in PBS
at pH 7.4, and the tubes were stored in the dark at 4°C for
up to 24 hours until flow-cytometric analysis could be per-
formed. Samples were analyzed by using a FACScan flow
cytometer equipped with Cell-Quest software. CaliBRITE-
3 beads and FACS COMP software were used on a weekly
basis to calibrate the fluorescence intensity in accordance
with the manufacturer’s instructions. Ten thousand neu-
trophils were collected from each sample with light-scatter
gain set in the linear mode and fluorescence gain set in
the logarithmic mode. The neutrophil population was
identified by light-scatter characteristics (forward versus
side-scatter) and enclosed in an electronic gate for fluores-
cence histogram analysis. Antibody binding was expressed
as mean fluorescence intensity (MFI), values for which
were corrected for nonspecific binding by subtracting MFI
measured for the matched isotype control sample.
Experiment 2
Subsequent to the findings of the first experiment, a sec-
ond experiment using 40 rats (eight animals randomized
to five groups, as in experiment 1) was performed to
determine the effects of the three doses of dopexamine on
cardiac output and mesenteric regional microvascular
flow. The same protocol was followed, as specified pre-
viously, except that, after laparotomy, bowel was evacuated
into a moist cotton receptacle. Blunt dissection was then
performed to access the abdominal vasculature. After iso-
lation from the vena cava, a 1.5-mm ultrasonic aortic tran-
sit time flow probe (MA1.5PRB; Transonic Systems Inc.,
Ithaca, NY, USA) was placed on the infrarenal aorta to
measure aortic blood flow. The bowel was then replaced
in the abdominal cavity, except for a loop of ileum just
proximal to the cecum. The exposed bowel was kept
moist by the application of 0.9% saline drops through a
pipette. The laparotomy incision above and below the exit
of the terminal ileal loop from the abdomen was then
closed with 5.0 Vicryl to prevent excessive insensible
losses. A 1.5-cm incision was subsequently made in the
antemesenteric border of the ileum by using unipolar dia-
thermy for later placement of laser Doppler probes. To
prevent thermal damage to the ileum, the section was
immediately washed with normal saline. The mucosal sur-
face of the bowel was exposed and gently cleansed with
0.9% saline by using cotton-tipped buds in preparation for
placement of laser Doppler probes. The animal was then
placed on a Perspex stage in the right lateral position so
that the ileal loop rested on a raised section of the stage, at
the level of the laparotomy incision. Subsequently the
bowel was fixed at two points on either side of the incision
with a small amount of tissue glue to prevent movement
artefact. After application of the laser Doppler probes (see
later), an impermeable cover for the ileal loop was created
by placing small pieces of pre-cut Saran wrap over the loop
and around the probes, until the ileal preparation was air-
tight. This was followed by a 5-ml/kg bolus of intravenous
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normal saline to replace insensible fluid losses and by a
15-minute stabilization period. Blood sampling for plasma
lactate and arterial blood gases was performed, followed by
a second 15-minute stabilization period before measure-
ment of regional microvascular flow. The only other blood
samples taken were at the end of the experiment for mar-
kers of organ injury.
Measurement of mesenteric red cell flux
Two fiberoptic laser Doppler flux slave probes (P10k;
Moor Instruments, Axminster, UK) suspended from
clamps were lightly applied to the mucosal and serosal
surfaces of the ileum to determine red-cell flux, a mea-
sure of regional microvascular blood flow. Two probes
were placed on the ileum, one on a mucosal site and
one on a serosal site away from visible blood vessels.
These were then fixed with tissue glue, a technique that
causes minimal interference with tissue microvascular
flow. Slave probes were calibrated daily by using PFS flux
standard (Moor Instruments, Axminster, UK) at 23°C
before experiments. Slave probes were attached to master
probes (MP10M200ST; Moor Instruments), which in
turn were connected to a satellite monitor (moorLAB;
Moor Instruments). Connection of the server to a desk-
top computer allowed continuous recording of red-cell
flux and the direct current or DC signal (index of
reflected light intensity and hence quality of probe con-
tact). Laser light of 780-nm wavelength with a 40-Hz
sampling rate and a 30-degree angular spread allowed a
sampling volume of approximately 1 mm3. The probe
readout was monitored for 2 minutes to ensure adequate
contact before fixation. As the thickness of rat ileum is
less than the depth of measurement achieved with LDF
probes, red-cell flux was averaged between mucosal and
serosal sites to minimize bias due to heterogeneity in
regional microvascular flow.
Measurement of aortic blood flow
A 1.5-mm perivascular probe was applied with water-
soluble sonicating gel and sited as described earlier. The
probe was connected to a TS420 monitor (Transonic
Systems Inc., Ithaca, NY, USA), which was connected to
a Powerlab/8SP monitoring system (AD Instruments).
This allowed continuous recording of aortic blood flow
and waveform-derived HR and calculation of a measure
of stroke volume. Aortic blood flow was indexed to
body weight to provide a measure of changes in stroke
volume index (SVI) and cardiac index (CI). Probe cali-
bration was performed daily according to the manufac-
turer’s instructions before experiments.
Statistical analysis
In both experiments, D’Agostino & Pearson Omnibus nor-
mality testing was performed on all data (Kolmogorov-
Smirnov testing if missing data points meant numbers in
the group were too small for this). Normally distributed
data was tested by using one-way analysis of variance
(ANOVA) for comparison across all groups at a given
time point, and two-way ANOVA, for changes in multiple
groups over time (that is, repeated measurements). Post-
testing was performed with Bonferroni tests. When data
were not normally distributed in at least one group for any
measurement (for example, urea, experiment 2), the Krus-
kal-Wallis test was used in place of one-way ANOVA, and
appropriate t tests against controls for posttesting were
used, depending on whether the individual groups were
normally distributed.
In each experiment, when no significant differences were
found between dopexamine groups, data were pooled and
compared against the corresponding control group by
using two-tailed unpaired t tests (normally distributed) or
Mann-Whitney tests otherwise. This occurred in the case
of base deficit, lactate, and organ function. Two-tailed
paired t tests were used to compare hemodynamics and
microvascular flow at baseline with end of experiment for
animals within the same group. Data were analyzed with
PrismGraph 4.0 (GraphPad Software, San Diego, CA,
USA). Significance was set at P < 0.05.
Results
Of a total of 3,740 measurements across the two experi-
ments, 33 either were missed because of equipment pro-
blems or were inaccurate. The numbers of absent data
points are referred to in the figure legends, and were
mostly related to measurements of serum base deficit,
lactate, cytokines, and integrin expression.
Experiment 1
No statistically significant differences were found
between control and other animals in terms of weight,
anesthetic dose, volume of fluid administered, HR, MAP,
base deficit, or lactate at baseline (see Additional file 1,
Table S1). Compared with sham animals, control animals
had a significantly higher HR (P < 0.05) at 4 hours and a
lower MAP (P < 0.01) compared with baseline at this
time (see Additional file 2, Table S2). At this point,
plasma lactate (P < 0.001) and base deficit (P < 0.01),
neutrophil cell surface CD11b expression (P < 0.001),
pulmonary tissue MPO activity (P < 0.01), and plasma
TNF-a (P < 0.01), IL-1b (P < 0.01), IL-6 (P < 0.001), and
IL-10 (P < 0.05) were also significantly higher in control
animals when compared with sham animals (Figures 1, 2,
3, and 4 and Additional file 3, Figure S1). Levels of
plasma TNF-a at 1 hour (that is, peak levels) were also
significantly higher in control animals (P < 0.001).
After LPS administration, CD11b expression increased in
control animals, whereas CD11a expression decreased
(Figure 2 and Additional file 4, Figure S2). Endotoxemia
resulted in significant organ injury, as evidenced by con-
trol-group plasma urea (P < 0.001), creatinine (P < 0.001),
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ALT (P < 0.001), and AST (P < 0.01) being significantly
greater than that of the sham group (Figures 5 and 6).
When compared with control animals, HR was higher in
the dopexamine groups at 4 hours after LPS, although
this was not statistically significant. Although MAP
decreased to a similar extent in controls and all dopexa-
mine groups, MAP was slightly better maintained in D2
animals (Additional file 2, Table S2, and Additional file 5,
Figure S3). The increase in plasma lactate was less in
dopexamine-treated animals than in control animals (P <
0.001 controls versus pooled dopexamine) with corre-
sponding changes in base deficit (P < 0.05 controls versus
pooled dopexamine) (Figure 1). Compared with control
animals, dopexamine at all doses also significantly attenu-
ated the increase in TNF-a (any dose, minimum P <
0.05), IL-1b (any dose, minimum P < 0.05), and IL-6 (any
dose, minimum P < 0.01) at 4 hours, whereas the
reduction in IL-10 achieved significance only at doses of
0.5 and 1 μg/kg/min (P < 0.05 minimum) (Figure 4;
Additional file 3, Figure S1). Peak plasma TNF-a was
also attenuated at these doses, although significantly in
only D2 animals (P < 0.05). CD11a expression was unaf-
fected by dopexamine (Additional file 4, Figure S2), but
in D1 and D2 groups, dopexamine infusion was asso-
ciated with significantly decreased CD11b expression at
4 hours (P < 0.01 minimum) (Figure 2), as well as signifi-
cantly reduced pulmonary MPO activity (P < 0.05 mini-
mum) (Figure 3). Notably, dopexamine infusion was also
associated with significant reductions in renal (P < 0.005
pooled dopexamine versus controls) and hepatic injury
(P < 0.05 pooled dopexamine versus controls) (Figures 5
and 6).
Figure 1 Plasma lactate (n = 8 for all groups) and base deficit (n = 8 all except D0.5 and D1 (n = 6 each)) at 4 hours after laparotomy
and endotoxemia, experiment 1. In control animals, lactate significantly increased compared with shams, whereas this was not observed in
dopexamine-treated animals (P < 0.001 pooled dopexamine versus control). A similar observation was made for base deficit (P < 0.05 pooled
dopexamine versus control). Data presented as mean (SEM). One-way ANOVA (Bonferroni posttests, *P < 0.05, **P < 0.01, ***P < 0.001 compared
with controls).
Figure 2 Circulating neutrophil surface CD11b mean
fluorescent intensity (MFI) at baseline and 4 hours after
laparotomy and endotoxemia (n = 6 controls, n = 8 all others),
experiment 1. No significant differences were found between
groups at baseline. Dopexamine was associated with smaller
increases in D1 and D2 groups compared with controls. Data
presented as mean (SEM). Two-way ANOVA (Bonferroni posttests,
**P < 0.01, ***P < 0.001 compared with controls).
Figure 3 Pulmonary myeloperoxidase (MPO) activity in lung
tissue sampled 4 hours after laparotomy and endotoxemia (n
= 4 each group), experiment 1. Dopexamine was associated with
smaller increases in D1 and D2 groups compared with controls.
Data presented as mean (SEM). One-way ANOVA (Bonferroni
posttests, *P < 0.05, **P < 0.01 compared with controls).
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Experiment 2
No statistically significant differences were found
between groups in terms of animal weight, dose of anes-
thetic administered, or volumes of fluid infused at base-
line (see Additional file 6, Table S3). Baseline MAP, HR,
CI, SVI, and lactate were not significantly different
between groups (see Additional file 7, Table S4; Addi-
tional file 8, Figure S4; and Additional file 9, Figure S5;
Figure 7). In the sham group, CI and SVI increased pro-
gressively (Figure 7 and Additional file 9, Figure S5),
whereas ileal flux decreased to a mean of 82% of baseline
over a 4-hour period (P < 0.05 versus baseline) (Figure 8).
In control-group animals, ileal flux also decreased over
time, but more rapidly and to levels below those observed
in sham animals (P < 0.05 minimum, from 30 minutes
onward) (Figure 8). This was associated with a moderate
but significant decrease in CI over 4 hours (P < 0.05
versus baseline) and a more-marked decrease in SVI over
the same period (P < 0.0005 versus baseline), possibly
reflecting the importance of compensatory tachycardia in
this model. By 4 hours, control-group plasma lactate (P <
0.01) and base deficit (P < 0.05) were significantly
increased compared with sham animals (Additional file 7,
Table S4). With regard to organ dysfunction, endotoxe-
mia in experiment 2 also resulted in organ injury,
although the changes did not reach statistical significance
for AST (see Additional file 10, Table S5).
The addition of dopexamine at any dose did not signifi-
cantly affect MAP (Additional file 7, Table S4, and
Additional file 8, Figure S4) and did not attenuate the
LPS-induced decreases in SVI and CI, despite a signifi-
cant increase in heart rate (Figure 7; Additional file 9,
Figure S5; Additional file 7, Table S4). Moreover, dopex-
amine did not influence the decrease in ileal red-cell
Figure 4 One-hour (peak) plasma TNF-a concentrations (n = 8 except controls and D2 (n = 7 each)) and 4 hours (n = 8 except D0.5,
D1, and D2 (n = 7, 6, and 5, respectively)) wing laparotomy and endotoxemia, experiment 1. Dopexamine was associated with smaller
increases in all groups at 4 hours, and in D2 at 1 hour, compared with controls. Data are presented as mean (SEM) for clarity at both time
points. However, not all data from 1 hour were normally distributed; the statistical analysis reflects this. One hour (t1): Kruskal-Wallis test (post hoc
Mann-Whitney tests, *P < 0.05, ***P < 0.001 compared with controls). Four hours (t4): One-way ANOVA (Bonferroni posttests *P < 0.05, **P <
0.01, ***P < 0.001 compared with controls).
Figure 5 Plasma urea and creatinine sampled 4 hours after laparotomy and endotoxemia (n = 8 all groups), experiment 1. Smaller
increases were observed in pooled dopexamine groups compared with controls (P < 0.005). Data presented as mean (SEM) when all groups
were normally distributed; otherwise, median (IQR) when more than one group were not normally distributed. Urea, one-way ANOVA (Bonferroni
posttests, **P < 0.01, ***P < 0.001 compared with controls). Creatinine: Kruskal-Wallis test (post hoc unpaired t tests (sham and D1), **P < 0.01
compared with controls; post hoc Mann-Whitney test (D2), *P < 0.05 compared with controls).
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flux (Figure 8), and in contrast to experiment 1, dopexa-
mine at any dose (and when dopexamine data were
pooled) was not associated with any significant differ-
ences in end-experiment plasma lactate, base deficit, or
organ function when compared with controls (Addi-
tional file 7, Table S4, and Additional file 10, Table S5),
with the exception of ALT in the D2 group (P < 0.05
versus controls).
Comparing experiments 1 and 2, groups were similar
with respect to baseline characteristics. By design, ani-
mals in experiment 2 received more fluid to compensate
for the more-sustained and severe surgical insult (Addi-
tional file 1, Table S1, and Additional file 6, Table S3).
Nevertheless, baseline HR, MAP, and lactate were similar
to those of equivalent groups in experiment 1 (Additional
file 2, Table S2, and Additional file 7, Table S4). How-
ever, an overall reduction in the severity of injury and
lactatemia appeared to occur in control animals in
experiment 2, as compared with experiment 1 (Addi-
tional file 7, Table S4, and Additional file 10, Table S5).
For completeness, standard deviations of data are pre-
sented for both experiment 1 (Additional file 11, Table S6)
and experiment 2 (Additional file 12, Table S7).
Discussion
This study showed that, in a rodent model of laparotomy
and endotoxemia, dopexamine can attenuate the systemic
inflammatory response, limit the degree of lactic acidosis,
and protect against organ injury. In the first experiment,
dopexamine infusion was associated with a reduced sys-
temic inflammatory response, as evidenced by decreased
circulating levels of TNF-a, IL-1b, and IL-6, and
decreased leukocyte expression of the cell-adhesion
molecule CD11b. In turn, this was associated with
reduced pulmonary MPO activity, a marker of pulmonary
leukocyte infiltration. Overall, dopexamine-treated ani-
mals sustained less organ injury than did control animals.
Interestingly, these potentially beneficial effects occurred
Figure 6 Plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) sampled four hours following laparotomy and
endotoxaemia (n = 8 all groups), experiment 1. Smaller increases were observed in pooled dopexamine groups compared with controls (P <
0.05). Data presented as mean (SEM). One-way ANOVA (Bonferroni posttests, *P < 0.05, **P < 0.01, ***P < 0.001, compared with controls).
Figure 7 Stroke volume index 4 hours after laparotomy and
endotoxemia, experiment 2. Stroke volume index decreased
significantly throughout the experiment, but no differences were
observed between controls and dopexamine-treated animals. Data
presented as mean (SEM). Two-way ANOVA (Bonferroni posttests **P
< 0.01, ***P < 0.001 sham compared with controls).
Figure 8 Regional microvascular flow (ileal red-cell flux) 4
hours after laparotomy and endotoxemia, experiment 2. Flow
decreased significantly throughout the experiment, but no
differences were observed between controls and dopexamine-
treated animals. Data presented as mean (SEM). Two-way ANOVA
(Bonferroni posttests, *P < 0.05, **P < 0.01, ***P < 0.001 sham
compared with controls).
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at doses of dopexamine that had little or no effect on
blood pressure and did not alter cardiac output or
mesenteric regional microvascular flow in the second
experiment.
Based on these findings, we suggest that after a com-
bined surgical and infectious insult, dopexamine can
attenuate the increase in circulating levels of inflammatory
mediators and reduce leukocyte expression of the cell-
adhesion molecule CD11b. As a consequence, leukocyte-
endothelial adhesion and transmigration into tissues is
decreased, with a reduction in organ injury. This sugges-
tion is consistent with the findings of previous studies indi-
cating that catecholamines can inhibit cytokine release
[16,22]. Although not intrinsically chemotactic, TNF-a
and IL-1b upregulate endothelial and leukocyte expression
of adhesion molecules [23,24], and hence promote leuko-
cyte-endothelial adhesion and migration into tissues.
Previous work also showed that adrenergic agents can
decrease leukocyte expression of adhesion molecules [25],
whereas in vivo microscopy suggests that dopexamine may
decrease leukocyte-endothelial adhesion in the mesenteric
circulation [16,17]. Dopexamine has been shown to
decrease free radical-mediated tissue injury in other animal
models [26,27], whereas the b2-agonist terbutaline reduced
nitric oxide and superoxide levels in endotoxemic rats [28].
These findings are consistent with our current understand-
ing of the important role played by endogenous catechola-
mines in the regulation of immune cell function [15].
In contrast to our recent clinical findings in high-risk
surgery patients [6], in the present study, these effects
were observed at doses of dopexamine that had little or no
effect on arterial pressure and did not alter cardiac output
or mesenteric regional microvascular flow, suggesting that
dopexamine has independent antiinflammatory actions
that can reduce inflammation and organ injury in this
model.
Our findings appear to contrast with those of a recent
small clinical trial performed by our group, which identi-
fied significant increases in tissue microvascular flow and
oxygenation but no changes in inflammatory mediators
after major surgery [6]. Several differences may explain
this. First, the time points at which serum was collected in
the clinical trial were not suitable for the identification of
a modified inflammatory response in dopexamine-treated
subjects. Second, differences in organ injury are more
readily identified in previously healthy rats than in patients
with significant comorbid disease. Notwithstanding these
differences, the findings of the clinical trial do not contra-
dict those of this more recent laboratory work.
A number of limitations complicate the interpretation
of these experiments. Although this model is one of com-
bined laparotomy and sepsis, it is impossible to evaluate
the effects of the surgery alone from the design, and dif-
ferences between groups are related to the effects of
treatment on sepsis, albeit in the setting of abdominal
surgery. Although the models used for the two experi-
ments were similar, we cannot be certain that the addi-
tional surgical preparation required for experiment 2 did
not cause hemodynamic differences between the two pre-
parations (for example, in regional microvascular flow).
However, the fact that values for HR, blood pressure, and
lactate at baseline and throughout the 4-hour experimen-
tal period were similar argues against this possibility. It
would have been preferable to perform all measurements
in one experiment rather than two, but as experiment 1
required 1.2 ml of blood (5% of the blood volume of a
300-g rat) to be intermittently sampled before 4 hours,
and laser Doppler flowmetry is exquisitely sensitive to
even minor changes in circulating volume, it was thought
that a separate experiment should be performed to assess
independently the effects of dopexamine and fluid on
microvascular flow in this setting.
It is also reassuring that many of the findings from the
current experiments are consistent with those of pre-
vious work, such as the reduction in regional microvas-
cular flux seen with LPS, as well as the amelioration of
renal dysfunction and downregulation of CD11b integ-
rins caused by dopexamine [16,25,29]. Many methods
have been used to evaluate the microcirculation in vivo,
each of which has limitations. Laser Doppler flowmetry,
as used here, may lack the sensitivity required to detect
small changes in flow heterogeneity of microvascular
flow. These changes may have been better detected by
other means of monitoring the microcirculation (for
example, intravital microscopy). Moreover deterioration
in the quality of ileal preparations over time is a recog-
nized phenomenon in microvascular studies involving
bowel exteriorization.
The failure to demonstrate improvements in regional
microvascular flow in experiment 2 might also be
explained by other differences between our model and
those in which dopexamine was shown to improve it.
These include but are not limited to endotoxin serotype
and fluid regimens [16,17]. The limited protective effect
of dopexamine in terms of organ injury might then
reflect the absence of improvements in regional micro-
vascular flow. It is also possible that the observed reduc-
tion in lactic acidosis was attributable to direct cellular
or metabolic mechanisms rather than being secondary
to improved tissue oxygenation [30,31].
Conclusions
In summary, these findings suggest that, in a rodent
model of laparotomy and endotoxemia, dopexamine at
doses within the clinical range can attenuate TNF-a
release, tissue leukocyte infiltration, and hence organ
injury at doses that do not alter global hemodynamics
or regional microvascular flow. These findings support
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the suggestion that the immunomodulatory effects of
catecholamines are likely to be clinically significant
when these agents are used in critically ill surgical
patients. Further research is required to explore the
potential benefits and possible dangers of immune mod-
ulation induced by adrenergic agents in clinical practice.
Key messages
• In a resuscitated model of normotensive sepsis and
surgical stress, the addition of clinically relevant
doses of dopexamine can attenuate the inflammatory
response and ameliorate organ dysfunction.
• This occurs at doses at which dopexamine appears
to have little additional effect on cardiac index,
stroke volume index, or regional microvascular flow.
Additional material
Additional file 1: Table S1. Baseline characteristics for experiment 1
(n = 8 all groups). Data presented as mean (SEM) when all groups were
normally distributed; otherwise, median (IQR) if more than one group
were not normally distributed.
Additional file 2: Table S2. Hemodynamic parameters, end-of-
experiment lactate and arterial blood gas data for experiment 1. All
groups hemodynamics and lactate, arterial blood gas data (pH, base deficit,
PaCO2, and PaO2) n = 8 (except D0.5 and D1 ABG data, n = 6; Control PaCO2
and PaO2 data only, n = 6). Data presented as mean (SEM) when all groups
were normally distributed; otherwise, median (IQR) if more than one group
were not normally distributed. One-way ANOVA (Bonferroni posttests, *P <
0.05, **P < 0.01, ***P < 0.001 versus controls). Final HR only: Kruskal-Wallis
tests (post hoc Mann-Whitney tests, *P < 0.05 versus controls).
Additional file 3: Figure S1. Plasma cytokine concentrations after
laparotomy and endotoxemia. (IL-1b: n = 8 sham and control, n = 7
D0.5, n = 6 D1, n = 4 D2; IL-6: all n = 8 except n = 7 control and
D2; IL-10: n = 8 sham and control, n = 7 D0.5 and D1, n = 6 D2),
experiment 1. Dopexamine was associated with smaller increases in all
groups compared with controls. Data presented as mean (SEM). One-way
ANOVA (Bonferroni posttests, *P < 0.05, **P < 0.01, ***P < 0.001
compared with controls).
Additional file 4: Figure S2. Circulating neutrophil CD11a mean
fluorescent intensity (MFI) at baseline and 4 hours after laparotomy
and endotoxemia (n = 7 D0.5; n = 8 all others), experiment 1. Data
presented as mean (SEM). Two-way ANOVA (Bonferroni posttests, *P <
0.05 compared with controls).
Additional file 5: Figure S3. Mean arterial pressure for all groups
(experiment 1) 4 hours after laparotomy and endotoxemia (n = 8
all groups). Data presented as mean (SEM).
Additional file 6: Table S3. Baseline characteristics for experiment 2
(n = 8 all groups). Data presented as mean (SEM) when all groups were
normally distributed; otherwise, median (IQR) if more than one group
were not normally distributed.
Additional file 7: Table S4. Hemodynamic parameters, end-of-
experiment lactate and arterial blood gas data for experiment 2. All
groups hemodynamics, lactate, and arterial blood gas data (pH, base
deficit, PaCO2, and PaO2) n = 8 (except D2, ABG data n = 7). Data
presented as mean (SEM). One-way ANOVA (Bonferroni posttests *P <
0.05, **P < 0.01, ***P < 0.001 versus controls).
Additional file 8: Figure S4. Mean arterial pressure for all groups
(experiment 2) 4 hours after laparotomy and endotoxemia (n = 8
all groups). Data presented as mean (SEM).
Additional file 9: Figure S5. Relative cardiac index for all groups
(experiment 2) 4 hours after laparotomy and endotoxemia (n = 8
all groups). Data presented as mean (SEM). Two-way ANOVA (Bonferroni
posttests, *P < 0.05, **P < 0.01, ***P < 0.001 compared with controls).
Additional file 10: Table S5. Plasma urea, creatinine, alanine
aminotransferase (ALT), and aspartate aminotransferase (AST)
sampled 4 hours after laparotomy and endotoxemia in experiment
2 (all n = 8). Data presented as mean (SEM) when all groups were
normally distributed; otherwise, median (IQR) if more than one group
was not normally distributed. Kruskal-Wallis test (urea and ALT: post hoc
Mann-Whitney test *P < 0.05, **P < 0.005, ***P < 0.001 versus controls).
Kruskal-Wallis test (creatinine: post hoc Unpaired t test, ***P < 0.001
versus controls).
Additional file 11: Table S6. Standard deviations of all data presented
in tables for experiment 1.
Additional file 12: Table S7. Standard deviations of all data
presented in tables for experiment 2.
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